Pages that link to "Q34107311"

The following pages link to Mechanism of action of niacin on lipoprotein metabolism (Q34107311):

Displaying 48 items.

• A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough (Q26824249) (← links)
• GPR109A and vascular inflammation (Q28287747) (← links)
• The therapeutic role of niacin in dyslipidemia management (Q28304559) (← links)
• Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Athero (Q33693952) (← links)
• Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials (Q33776194) (← links)
• Partitioning of homologous nicotinic acid ester prodrugs (nicotinates) into dipalmitoylphosphatidylcholine (DPPC) membrane bilayers. (Q33862278) (← links)
• Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells (Q34333955) (← links)
• Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans (Q34597967) (← links)
• The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations (Q34727571) (← links)
• Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity (Q34990615) (← links)
• Niacin extended-release/lovastatin: combination therapy for lipid disorders (Q35020544) (← links)
• Visceral obesity in normal-weight patients suffering from chronic schizophrenia (Q35088980) (← links)
• Effects of niacin on atherosclerosis and vascular function (Q35132366) (← links)
• Niacin and cholesterol: role in cardiovascular disease (review). (Q35182214) (← links)
• Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment (Q35203793) (← links)
• The risk of dementia in relation to statins and other lipid lowering agents. (Q35540369) (← links)
• Niacin, lipids, and heart disease (Q35559539) (← links)
• New lipid-lowering agents (Q35602647) (← links)
• The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin (Q35637978) (← links)
• Extended-release niacin/lovastatin: the first combination product for dyslipidemia (Q35821875) (← links)
• High-density lipoprotein subfractions and risk of coronary artery disease (Q35856884) (← links)
• The effects of niacin on lipoprotein subclass distribution (Q35946780) (← links)
• Pharmacologic treatment of type 2 diabetic dyslipidemia (Q35976827) (← links)
• Niacin in cardiovascular disease: recent preclinical and clinical developments (Q36084389) (← links)
• Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice (Q36302760) (← links)
• Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS). (Q36303713) (← links)
• Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol (Q36540320) (← links)
• A network biology model of micronutrient related health (Q37206355) (← links)
• The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient (Q37311116) (← links)
• Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders (Q37329136) (← links)
• Plant amino acid-derived vitamins: biosynthesis and function. (Q38173828) (← links)
• Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs (Q38546242) (← links)
• Multivalent niacin nanoconjugates for delivery to cytoplasmic lipid droplets (Q39632948) (← links)
• Reduced high-density lipoprotein 2b in non-obese type 2 diabetic patients analysed by a microfluidic chip method in a case-control study (Q43277962) (← links)
• Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia (Q43919588) (← links)
• Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus (Q44006878) (← links)
• Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). (Q44359910) (← links)
• Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. (Q44406779) (← links)
• Effects of extended-release niacin on lipoprotein subclass distribution (Q44476840) (← links)
• The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy (Q44652704) (← links)
• Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity? (Q45101365) (← links)
• Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome. (Q51316398) (← links)
• Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes (Q59798260) (← links)
• Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan (Q79773529) (← links)
• Sesamol treatment reduces plasma cholesterol and triacylglycerol levels in mouse models of acute and chronic hyperlipidemia (Q86415362) (← links)
• Determination of niacin profiles in some animal and plant based foods by high performance liquid chromatography: association with healthy nutrition (Q92108539) (← links)
• Niacin regulates apolipoprotein M expression via liver X receptor‑α (Q92738315) (← links)
• Systemic vitamin intake impacting tissue proteomes (Q99630037) (← links)